Fubangde Ainuovirine Lamivudine and Tenofovir Disoproxil Fumarate Tablets

1. Indications and Usage
HIV-1 Infection: Indicated for the treatment of HIV-1 infected naive adult patients.
Combination Requirement: It must be used in combination with other antiretroviral agents and should not be used as monotherapy.
2. Dosage and Administration
Recommended Dose: The recommended dose is taken orally once daily.
Administration: The tablets must be taken on an empty stomach to avoid increased drug exposure and adverse reactions.
Renal Impairment: Dosage adjustment is required for patients with severe renal impairment (creatinine clearance <30 mL/min).
3. Mechanism of Action
NNRTI Activity: Ainuovirine selectively inhibits the HIV-1 reverse transcriptase enzyme, preventing the conversion of viral RNA into DNA.
NRTI Activity: Lamivudine and Tenofovir Disoproxil Fumarate are nucleoside/nucleotide analogues that, after intracellular phosphorylation, compete with natural substrates and cause chain termination during DNA synthesis.
Synergistic Effect: The combination of these three agents with distinct mechanisms provides potent suppression of viral replication and reduces the risk of cross-resistance.
4. Safety and Warnings
Hepatotoxicity: Liver enzyme elevations (ALT, AST, γ-GT) and severe drug-induced liver injury have been reported.
Renal Impairment: The Tenofovir component may cause acute renal failure, worsening of chronic renal failure, and proximal renal tubule dysfunction.
Immune Reconstitution Inflammatory Syndrome (IRIS): May occur in the initial phase of treatment as the immune system recovers.
Lipid Metabolism: Increases in triglycerides and cholesterol may occur during therapy.
Bone Mineral Density: Tenofovir is associated with decreases in bone mineral density.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include rash, diarrhea, headache, fatigue, elevated liver enzymes, and nausea.
Clinical Research: Phase III clinical trials demonstrated that this regimen-based regimen achieved high rates of viral suppression and was non-inferior to standard regimens.
6. Drug Interactions
CYP2C19 Inducers: Drugs like rifampin or carbamazepine may accelerate ainuovirine metabolism, reducing plasma concentrations.
CYP2C19 Inhibitors: Drugs like omeprazole or ketoconazole may inhibit metabolism, increasing plasma concentrations and toxicity risks.
Nephrotoxic Agents: Concomitant use with other nephrotoxic drugs (e.g., high-dose NSAIDs, aminoglycosides) may increase the risk of renal toxicity.
Other Antiretrovirals: Concomitant use with other non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, nevirapine) may lead to cross-resistance.
7. Pharmaceutical Information
Composition: The active ingredients are ainuovirine, lamivudine, and tenofovir disoproxil fumarate.
Appearance: Available as film-coated tablets.
Storage: Store in a tightly sealed container, protected from light and moisture, at a temperature not exceeding 30°C.